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Dengue poses a serious public health risk to nearly half the global population. It
causes ∼400 million infections annually and is considered to be one of the fastest
spreading vector-borne diseases. Four distinct serotypes of dengue viruses (DENV-1,
-2, -3, and -4) cause dengue disease, which may be either mild or extremely severe.
Antibody-dependent enhancement (ADE), by pre-existing cross-reactive antibodies, is
considered to be the major mechanism underlying severe disease. This mandates that a
preventive vaccine must confer simultaneous and durable immunity to each of the four
prevalent DENV serotypes. Recently, we used Pichia pastoris, to express recombinant
DENV-2 E ectodomain, and found that it assembled into virus-like particles (VLPs), in the
absence of prM, implicated in the elicitation of ADE-mediating antibodies. These VLPs
elicited predominantly type-specific neutralizing antibodies that conferred significant
protection against lethal DENV-2 challenge, in a mouse model. The current work is an
extension of this approach to develop prM-lacking DENV-3 E VLPs. Our data reveal
that P. pastoris-produced DENV-3 E VLPs not only preserve the antigenic integrity
of the major neutralizing epitopes, but also elicit potent DENV-3 virus-neutralizing
antibodies. Further, these neutralizing antibodies appear to be exclusively directed
toward domain III of the DENV-3 E VLPs. Significantly, they also lack discernible ADE
potential toward heterotypic DENVs. Taken together with the high productivity of the
P. pastoris expression system, this approach could potentially pave the way toward
developing a DENV E-based, inexpensive, safe, and efficacious tetravalent sub-unit
vaccine, for use in resource-poor dengue endemic countries.
Keywords: dengue, dengue envelope, dengue vaccine, virus-like particle (VLP), neutralizing antibody, antibody-
dependent enhancement (ADE), Pichia pastoris
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Introduction
Dengue is currently regarded by the World Health Organization
(WHO) as one of the fastest spreading vector-borne diseases
(World Health Organization [WHO], 2012). It is prevalent
in >100 countries around the world, placing >2.5 billion
people at risk. Recent estimates indicate that there may be
as many as 400 million infections annually (Bhatt et al.,
2013). The disease, which is caused by four closely related,
but antigenically distinct, serotypes of dengue viruses (DENV-
1, -2, -3, and -4), is spread to humans by mosquitoes of
the genus Aedes. Dengue infections may be inapparent, mild
[dengue fever, (DF)] or severe [dengue hemorrhagic fever
(DHF), and dengue shock syndrome (DSS], with potentially fatal
outcomes in the absence of medical care (Gubler et al., 2007;
Swaminathan and Khanna, 2009; World Health Organization
[WHO], 2015). The severe disease is believed to be the
result of pre-existing cross-reactive antibodies which apparently
facilitate uptake of heterotypic DENVs into monocytes and
macrophages through FcγR pathway, a phenomenon termed
as antibody-dependent enhancement (ADE; Halstead, 2003;
Gubler et al., 2007). This situation warrants a safe dengue
vaccine to confer simultaneous and durable immunity to each
of the four prevalent DENV serotypes. This, together with
lack of clear definition of correlates of protection and a
reliable animal model have made dengue vaccine an elusive
goal. The challenges inherent in dengue vaccine development
are underscored by the lack of clarity on efficacy despite the
conclusion of three efficacy trials to date, of a live attenuated
vaccine (LAV) candidate for dengue (Sabchareon et al., 2012;
Capeding et al., 2014; Villar et al., 2015). This, and the
uncertainty associated with LAVs stemming from the potential
for imbalances in immunity due to immune interference
(Edelman, 2011; Thomas, 2011; Swaminathan et al., 2013) have
re-focused attention on dengue vaccine initiatives based on
non-replicating sub-unit vaccine candidates (Schmitz et al.,
2011).
In this context, it is noteworthy that several viral structural
proteins possess an intrinsic potential to self-assemble
into virus-like particles (VLPs). It is well-documented that
structural proteins of many viruses, produced recombinantly
in heterologous hosts, form VLPs (Chackerian, 2007; Wang
et al., 2009; Liu et al., 2010; Kuwahara and Konishi, 2010; Tang
et al., 2012). The unique feature of the VLP is that it displays
repetitive epitope arrays on its surface, while at the same time
lacking infectious viral genomic material. Thus, the VLP is not
only highly immunogenic, capable of eliciting a robust immune
response, but also safe, as it is non-infectious (Bachmann and
Jennings, 2010; Yildiz et al., 2011). This makes the VLP an ideal
vaccine platform, as evidenced by the success of VLP vaccines for
hepatitis B and human papilloma virus infections (Chackerian,
2007).
In the context of DENV, the major structural antigen from
the perspective of a vaccine candidate is the envelope (E)
glycoprotein. This is a large, ∼500 amino acid (aa) residue
protein, whose C-terminal ∼100 aa residues are embedded
in the host-membrane on the surface of the mature virion
(Lindenbach et al., 2007). The N-terminal 80% (known as the
ectodomain) is organized into distinct sub-domains, envelope
domain I (EDI), EDII, and EDIII, stabilized by six S–S linkages
(Modis et al., 2003). Of these, EDIII which is implicated in host
receptor recognition, also contains multiple potent and type-
specific neutralizing epitopes (Gromowski and Barrett, 2007;
Shrestha et al., 2010). The minor structural protein, prM, which
has a role in virus maturation (Lindenbach et al., 2007), is
implicated in the induction of antibodies that can mediate ADE
(Dejnirattisai et al., 2010; Rodenhuis-Zybert et al., 2010). Reports
in the literature have led to the conclusion that co-expression
of both these DENV structural proteins in heterologous host
systems is required to produce VLPs (Wang et al., 2009;
Liu et al., 2010; Kuwahara and Konishi, 2010; Tang et al.,
2012).
Recently, using the methylotrophic yeast Pichia pastoris as
the expression host, we showed that the DENV-2 E ectodomain,
assembled into highly immunogenic VLPs. It is significant that
these VLPs were formed in the absence of prM and induced
potent DENV-2 virus-neutralizing antibodies which conferred
significant protection against lethal challenge in a mouse model
(Mani et al., 2013). The lack of prM eliminates the associated risk
of ADE from these VLPs and is clearly a safety advantage. From
the perspective of inexpensive production of recombinant sub-
unit vaccines, the availability of a very strong methanol-inducible
alcohol oxidase 1 (AOX1) promoter, the propensity of P. pastoris
to grow to high cell densities in simple inexpensive media,
its capacity for high productivity and ability to execute post-
translational modifications, make this yeast a robust and desirable
heterologous expression system (Macauley-Patrick et al., 2005).
This opens up the feasibility of developing an inexpensive, safe
and efficacious tetravalent sub-unit vaccine based on P. pastoris-
produced E VLPs of all four DENV serotypes. In a step in this
direction, we demonstrate in the current work that it is possible
to adopt a similar approach to create DENV-3 E (ectodomain)
VLPs (hereafter referred to as DENV-3 E VLPs for simplicity).
We further show that these VLPs elicit potent virus-neutralizing
antibodies. Interestingly, the neutralizing antibodies elicited by
the DENV-3 E VLPs appear to be predominantly homotypic, that
is, specific to DENV-3. Antibody depletion experiments suggest
that the neutralizing antibodies are exclusively directed toward
the EDIII of the DENV-3 E VLPs. Importantly, the antibodies
elicited by the DENV-3 E VLPs did not manifest significant
ADE.
Materials and Methods
Ethics Statement
Animal experiments strictly adhered to the guidelines set
out by the Committee for the Purpose of Control and
Supervision of Experiments on Animals (CPCSEA), Government
of India. Animal experimental protocols were approved by
the Institutional Animal Ethics Committees of International
Centre for Genetic Engineering & Biotechnology, New Delhi,
and Syngene International Limited, Bangalore (IAEC No.
Syngene/IAEC/520/06-2014).
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DENV-3 E Gene, Plasmid, Cell Hosts, Viruses
and Other Reagents
The DENV-3 E gene (∼1.4 Kb, GenBank accession no:
JX292266) was custom-synthesized by BioBasic Inc., Canada.
This synthetic gene was codon-optimized for expression in
P. pastoris. P. pastoris strain KM71H and plasmid pPICZ-A
were from Invitrogen Life Technologies (Carlsbad, CA, USA).
pPICZ-A is an integrative plasmid which provides the methanol-
inducible AOX1 promoter for transgene expression and the
zeocin resistance marker for selection. Vero and BHK 21 cell lines
were from American Type Culture Collection (ATCC), Virginia,
USA. The WHO reference DENV-1, DENV-2, DENV-3, and
DENV-4 viruses were the same as reported earlier (Kraus et al.,
2007). Ni2+-NTA His-Sorb plates and Ni2+-NTA Super-flow
resin were obtained from Qiagen (Hilden, Germany). DENV-2
EDIII-specific mAb 24A12 (Mani et al., 2013) and prM-specific
2H2 mAb (Martin et al., 2006) have been reported earlier.
4G2 mAb was from ATCC. All other type-specific and cross-
reactive human and murine mAbs have been described before
(Henchal et al., 1982; Brien et al., 2010; Shrestha et al., 2010;
Sukupolvi-Petty et al., 2010, 2013; Wahala et al., 2010; De
Alwis et al., 2011; Smith et al., 2012, 2013). Secondary antibody
conjugates for ELISA [anti-mouse IgG antibody-horseradish
peroxidase (HRPO)] and indirect immunofluorescence assay
(IFA) [IgG-fluorescene isothiocyanate (FITC) conjugates] were
from Calbiochem, La Jolla, CA, USA. The HRPO substrate 3,
3′, 5, 5′-Tetramethylbenzidine (TMB), Concanavalin A (Con A)-
HRPO conjugate and acid-washed glass beads (425–600microns)
were purchased from Sigma–Aldrich, St. Louis, MO, USA.
Uranyl acetate was from TAAB Laboratories Equipment Ltd
(UK).
Expression and Purification of Recombinant
DENV-3 E
TheDENV-3 E gene was integrated into the genome of P. pastoris
(strain KM71H) under the control of the AOX1 promoter as
done earlier for DENV-2 E gene. Expression was induced using
methanol and the recombinant protein purified under denaturing
conditions, using Ni2+ affinity chromatography, essentially as
described before (Mani et al., 2013). The purified protein was
characterized by SDS-PAGE, Western blot analysis and His Sorb
ELISA (using mAb 24A12), protein blotting (with Con A-HRPO)
to assess glycosylation status, and N-terminal sequence analysis,
as reported recently (Mani et al., 2013).
Antigenic integrity of epitopes on the DENV-3 E protein was
assessed using indirect ELISA. These ELISAs were done using
purified P. pastoris-produced DENV-3 E as the coating antigen
and a battery of previously reported type-specific and cross-
reactive human and murine mAbs (Henchal et al., 1982; Brien
et al., 2010; Shrestha et al., 2010; Sukupolvi-Petty et al., 2010,
2013; Wahala et al., 2010; De Alwis et al., 2011; Smith et al., 2012,
2013).
To examine VLP formation, purified DENV-3 E protein was
examined by electron microscopy as described (Arora et al.,
2012). Particle size and distribution of the VLPs (at 300 μg/ml in
20 mM Tris-HCl, pH8.5, containing 50 mMNaCl) were analyzed
by Dynamic Light Scattering (DLS), using Malvern Zetasizer
Nano Z.
Mouse Immunization and Seroanalysis
Groups (n = 6) of ∼6-week old BALB/c mice were immunized
intra-peritoneally with 20 μg purified recombinant DENV-3 E
antigen coated on alum, on days 0, 30, and 90, and sera collected
∼7 days after the first and second boosts, as reported (Mani et al.,
2013).
Antibodies induced by DENV-3 E VLPs were analyzed
by indirect ELISAs and indirect IFA, essentially as described
recently (Mani et al., 2013). Homotypic (specific to DENV-3)
and heterotypic (specific to DENV-1, -2, and -4) neutralizing
antibody titers were determined using a Fluorescence Activated
Cell Sorting (FACS)-based assay (Kraus et al., 2007), as done
earlier for anti-DENV-2 E VLP antiserum (Mani et al., 2013).
In some experiments the immune serum was depleted of
antibodies specific to EDIII of DENV-3 E protein (EDIII-3),
before being used in the FACS-based neutralization assay.
Depletion was accomplished by pre-incubating the immune
serum with amylose bound to maltose-binding protein (MBP)
fused in-frame to EDIII-3. Depleted serum was then incubated
with DENV-3 followed by infection of Vero cells and FACS
analysis. Control sample was depleted using amylose-MBP
instead of the fusion protein.
Fluorescence Activated Cell-based Neutralization Titer
(FNT50) of the immune serum was defined as serum dilution
resulting in a 50% reduction in the number of DENV-infected
cells (with reference to DENV infection in the absence of
immune serum).
Homotypic and heterotypic ADEwas evaluated using a similar
FACS-based assay, with the exception that FcγR-bearing K562
cells were used instead of Vero cells. The magnitude of ADE was
expressed as fold-enhancement (percentage of K562 cells infected
in the presence of antiserum divided by the corresponding
percentage in the absence of antiserum).
Statistical Analysis
Statistical significance of the difference between data sets was
determined by two-tailed Student t-test, using GraphPad Prism
software for Windows. Probability (p) levels less than 0.05 were
considered as significant.
Results
Yeast-Expressed DENV-3 E Antigen Assembles
into VLPs
We created a synthetic DENV-3 E gene and cloned it into
the expression vector pPICZ-A under the control of the AOX1
promoter, incorporated it into the genome of the P. pastoris
host strain KM71H, and verified its expression after methanol
induction using mAb 24A12 (Supplementary Figures S1 and S2),
as reported earlier (Mani et al., 2013). As seen for DENV-2 E,
the DENV-3E protein was also associated with the membrane
fraction in the induced cell lysate. It was, therefore, purified
under denaturing conditions (Supplementary Figure S3) from
Frontiers in Microbiology | www.frontiersin.org 3 September 2015 | Volume 6 | Article 1005
Tripathi et al. Dengue envelope-containing virus-like particles
the membrane-enriched fraction using the Ni2+-NTA affinity
chromatography method designed earlier for DENV-2 E protein
purification (Mani et al., 2013). Further, as observed in the case
of DENV-2 E protein, the DENV-3 E protein was also processed
appropriately in P. pastoris, based on N-terminal sequencing and
glycosylation studies. Yield of the purified recombinant DENV-3
E protein was ∼15 mg/L induced culture.
We had observed earlier that the P. pastoris-expressed DENV-
2 E protein is able to assemble into VLPs in the absence of prM
(Mani et al., 2013). We therefore expected that the DENV-3 E
protein produced using this yeast may alsomanifest this attribute.
To verify this, we analyzed the purified recombinant DENV-
3 E protein preparation by electron microscopy after negative
staining with uranyl acetate, as shown in Figure 1A. Consistent
with expectation, the ectodomain of DENV 3 E protein formed
discrete VLPs, in the absence of prM. Given that purification
was carried out in the presence of urea, VLP formation
presumably occurred upon gradual urea removal during dialysis.
The observation that P. pastoris-expressed recombinant DENV-
3 E protein ectodomain assembles into VLPs is consistent with
the behavior of its DENV-2 E counterpart, reported earlier (Mani
et al., 2013). The EM data reveal that the DENV-3 VLPs ranged in
size from 25 to 50 nm. Further, EM analysis revealed the VLPs to
be intact after 2 weeks incubation at 37◦C (data not shown). We
also analyzed particle size in purified DENV3 E VLP preparation
by laser-based DLS. This technique which monitors Brownian
movement of the VLPs in native solution can yield information
pertaining to average size and frequency distribution of particles.
As shown in Figure 1, DLS data represented on the basis of
either intensity (Figure 1B) or volume (Figure 1C), resulted in
quite similar particle size distribution profiles with average VLP
diameter of ∼47 nm, which was in fair agreement with EM data.
Overall Domain Architecture and Epitope
Integrity of DENV-3 E are Preserved in the
VLPs
We carried out an extensive immunological characterization of
the yeast-expressedDENV-3 EVLPs using a panel of type-specific
and cross-reactive murine and human mAbs obtained using E,
EDI/II, EDIII and fusion loop antigens. For this, we employed
an indirect ELISA using purified DENV-3 E VLPs as the coating
antigen, followed by detection of DENV-3 E VLP-bound mAbs
using cognate secondary Ab-HRPO enzyme conjugate (Table 1).
For a comparison, we performed this ELISA in parallel using
our P. pastoris-produced DENV-2 E VLPs, reported earlier (Mani
et al., 2013). DENV-3 mAbs E3, E4, and E12, all specific to
EDI/II region of the DENV-3 E antigen (Brien et al., 2010)
bound efficiently to DENV-3 E VLPs (but not to DENV-2 E
VLPs), suggesting that the EI/II region of the E antigen retains its
native antigenic structure in the DENV-3 E VLPs. This is further
supported by the observation that the DENV-3 E VLPs are also
recognized by EI/II epitope-specific cross-reactive mAbs such as
E17 (Brien et al., 2010) and h-23.13 (De Alwis et al., 2011), with
the former binding more efficiently. In addition, the DENV-3 E
VLPs also were recognized by human mAbs h-1N5 and h-1M7
(Smith et al., 2013), and the murine mAb 4G2 (Henchal et al.,
1982). These mAbs are specific to the fusion loop of the DENV E
protein.
The DENV-3 E VLPs were also recognized efficiently by
DENV-3 mAbs E1 (Brien et al., 2010) and 8A1 (Wahala et al.,
2010). Both these are type-specific mAbs that manifest binding to
EDIII of DENV-3. EDIII contains the lateral ridge (LR) epitope
(constituted by aa residues 301, 302, 329, 330, and 386) and elicits
potent virus-neutralizing antibodies (Gromowski and Barrett,
2007; Shrestha et al., 2010). While mAb E1 binds to an aa residue
in the vicinity of the LR epitope (aa 340), mAb 8A1 interacts
with several LR epitope aa residues. This is a DENV-3 specific
mAb which is reported to neutralize several, but not all, DENV-3
genotypes (Wahala et al., 2010). Consistent with this, mAbs E77
(Brien et al., 2010), 12C1 (Wahala et al., 2010), DV1E42 (Shrestha
et al., 2010), and h-2J20 (Smith et al., 2012) alsomanifested strong
reactivity toward the DENV-3 E VLPs. These mAbs manifest
cross-reactivity toward conserved EDIII epitopes. mAb E77 binds
to the LR epitope (Brien et al., 2010), while mAb 12C1 binds to
EDIII determinants outside the LR epitope (Wahala et al., 2010).
Collectively, these data lead to the conclusion that DENV-3 E
VLPs largely preserve the antigenic integrity of EDIII. Overall,
it can be said that the DENV-3 E VLPs were recognized quite
efficiently by mAbs specific to EDI/II, the fusion loop and EDIII.
Finally, the DENV-3 E VLPs were not recognized by any of the
DENV-1, DENV-2, or DENV-4 type-specific anti-E or anti-EDIII
mAbs specific to serotype 1, 2, and 4 (Table 1). That this lack
FIGURE 1 | Detection of virus-like particles (VLPs) in the purified DENV-3 E protein preparation. (A) EM analysis of freshly purified DENV-3 E antigen
following negative staining with 1% uranyl acetate. (B) Dynamic Light Scattering (DLS) analysis of particle size distribution by intensity. (C) DLS analysis of particle
size distribution by volume.
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of reactivity was not due to non-functional mAbs was ruled out
by testing them against their cognate type-specific antigens. For
example, ELISA optical density values for mAbs E24, E29, and
TABLE 1 | Analysis of antigenic integrity of DENV-3 and DENV-2 E VLPsa.
Type-specificmurine mAbs
mAbb Epitope specificity Absorbance, 450 nm
DENV-3 E DENV-2 E
DENV1 E24 EDIII 0.03 0.02
DENV1 E29 EDIII 0.09 0.03
DENV1 E37 EDIII 0.03 0.02
DENV1 E103 EDIII, LR 0.06 0.06
DENV-2 3H5 EDIII, LR 0.06 3.46
DENV-2 106 EDIII, LR 0.03 2.50
DENV-2 70 EDIII AS, LR 0.03 0.92
DENV-2 104 EDIII, C-C’ loop 0.10 3.45
DENV-3 E3 EDI/II 2.90 0.02
DENV-3 E4 EDI/II 3.18 0.04
DENV-3 E12 EDI/II 3.24 0.07
DENV-3 E1 EDIII 3.43 0.03
DENV-3 8A1 EDIII, LR 1.35 0.02
DENV-4 E88 EDIII, LR 0.03 0.07
DENV-4 E29 EDIII, F/G strand 0.03 0.04
DENV-4 E2 E 0.03 0.03
DENV-4 E42 E 0.02 0.02
DENV-4 E43 E 0.02 0.02
Cross-reactive murine and human mAbs
mAb Epitope specificity Absorbance, 450 nm
DENV-3 E DENV-2 E
E17c EDI/II 3.45 3.47
4G2d Fusion loop 0.83 0.20
12C1d EDIII, not LR 3.72 3.86
E42c EDIII 3.09 2.40
E77Com EDIII, AS, LR 2.41 1.21
h-23.13d EDI/II 0.52 0.10
h-1N5d Fusion loop 1.47 0.45
h-1M7d Fusion loop 2.48 3.03
h-2J20 EDIII 3.58 3.46
aDetermined by indirect ELISA using P. pastoris-produced purified DENV E VLPs
as coating antigens.
bThe type-specific mAbs used are described in literature: DENV-1 mAbs E24, E29,
E37, and E103 (Shrestha et al., 2010); DENV-2 mAb 3H5 (Henchal et al., 1982);
DENV-2 mAbs 70, 104, and 106 (Sukupolvi-Petty et al., 2010); DENV-3 mAbs E1,
E3, E4, and E12 (Brien et al., 2010); DENV-3 mAb 8A1 (Wahala et al., 2010); DENV-
4 mAbs E2, E29, E42, E43, and E88 (Sukupolvi-Petty et al., 2013). Cross-reactive
mAbs: E42 (Shrestha et al., 2010), 4G2 (Henchal et al., 1982); E17 and E77 (Brien
et al., 2010); 12C1 (Wahala et al., 2010); h23.13 (De Alwis et al., 2011); h-2J20
(Smith et al., 2012); h-IN5 and h-1M7 (Smith et al., 2013). All mAb are murine,
except the last four which are human (prefixed ‘h’).
cSub-complex-specific mAbs; E17 recognizes EDI/II of DENV-1 and DENV-3; E42
binds EDIII of DENV-1, DENV-2 (weak) and DENV-3.
dComplex-specific mAbs; 4G2, h-1N5, and h-1M7 bind the fusion loop of all four
DENV Es; 12C1 binds recombinant EDIII (outside the LR epitope) of all four DENV
serotypes.
E103 with MBP-EDIII-1 as the coating antigen were 3.11, 3.11,
and 3.5, respectively. Similarly, mAbs E88 and E423 manifested
comparable reactivity toward MBP-EDIII-4 antigen. Overall, the
data strongly support the conclusion that the DENV3 E VLPs
possess E epitopes essentially typical of DENV-3 serotype.
DENV-3 E VLPs are Immunogenic and Elicit
Virus-Specific Antibodies
The immunogenicity of the DENV-3 E VLPs above was evaluated
in BALB/c mice using a three-dose regimen as described (Mani
et al., 2013). Antibody titers in immune sera collected from these
mice were determined using an indirect ELISA, with purified
DENV-3 E VLPs as the coating antigen (Figure 2). Consistent
with that seen earlier for DENV-2 E VLPs, we found an immune
boosting effect with DENV-3 E VLPs as well (Figure 2A). As
a result, the next ELISA was done using sera collected after
the second boost. In this experiment, shown in Figure 2B,
we examined the capacity of DENV-3 E VLP immune sera
to cross-react with DENV-2 E VLPs as the coating antigen.
This showed that ELISA reactivity toward DENV-2 E VLPs was
∼20–25% that seen toward DENV-3 E VLPs. This decrease was
statistically significant (p < 0.05). Interestingly, ELISA titers
observed when the coating antigen used was the recombinant
EDIII protein, revealed that antibodies elicited by DENV-3 E
VLPs predominantly recognize EDIII-3 as the coating antigen.
The reactivity toward EDIII of serotype 2 was very significantly
lower (p< 0.01), and negligible in the case of EDIIIs of serotypes
1 and 4. This suggests that DENV-3 E VLPs tend to induce largely
serotype 3-specific antibodies. As a next step, we investigated if
these anti-DENV-3 E antibodies would also recognize and bind to
infectious DENV-3, using an indirect IFA. The data in Figure 2C
show that the DENV-3 E-induced antibodies can efficiently bind
to DENV-3 E in infected BHK-21 cells. As in the case of DENV-2
seen earlier (Mani et al., 2013), the immunofluorescence pattern
observed using anti-DENV-3 E VLPs antiserum showed DENV-3
replication to be essentially localized to the cytoplasm.
DENV-3 E VLPs Induce Predominantly
EDIII-Specific Homotypic and Potently
Neutralizing Antibodies
Following this preliminary analysis of the antibodies elicited
by the DENV-3 E VLPs, we next sought to determine if these
could prevent DENV from infecting susceptible cells. To this
end, we employed a FACS-based virus neutralization assay, the
results of which are depicted in Figure 3A. In this experiment
we tested the neutralization capacity of the DENV-3 E VLP
immune sera against each one of the four WHO reference
DENV strains (Kraus et al., 2007). Our data revealed that
the anti-DENV-3 E VLP antibodies neutralized only DENV-3
most effectively (FNT50 titers > 2400). The remaining three
serotypes were only weakly neutralized, with neutralization titers
against DENV-1, DENV-2, and DENV-4 being 1–5% the titers
observed for DENV-3. Heterotypic neutralization titers were very
significantly lower compared to homotypic neutralization titers
(p< 0.0001).
Given that the previous ELISA data (Figure 2B) showed
the predominant reactivity of DENV-3 E VLP-induced immune
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FIGURE 2 | Preliminary analysis of anti-DENV-3 E VLP induced antibodies. (A) Pooled sera from DENV-3 E VLP-immunized mice after the first (open blue
squares) and second (filled blue squares) boosts and mock-immunized (gray filled squares) BALB/c mice were tested in an indirect ELISA using DENV-3 E protein as
the coating antigen. (B) Anti-DENV-3 E antiserum obtained after the second boost was tested in ELISAs using DENV-2 E VLPs (solid green), DENV-3 E VLPs (solid
blue), recombinant monovalent EDIII-1 (dashed, red), EDIII-2 (dashed, green), EDIII-3 (dashed, blue) or EDIII-4 (dashed, black) proteins as the coating antigens. The
ELISA profile of sera from mock-immunized mice (dashed, gray) is found to be superimposed over that of the immune serum against EDIII-4 as the coating antigen.
(C) Indirect immunofluorescence analysis of DENV-3 virus-infected BHK-21 cells using (i) mock-immunized serum, (ii) 4G2 mAb, or (iii) anti-DENV-3 E antiserum, as
the source of primary antibodies. Bound antibodies were visualized using anti-mouse IgG-FITC conjugate.
FIGURE 3 | Characterization of neutralization potency of DENV-3 E VLP induced antibodies. (A) Two-fold serial dilutions of heat inactivated immune serum
from DENV-3 E VLP-immunized mice was assessed for its potency to neutralize and inhibit the infectivity of DENV-1 (red), DENV-2 (green), DENV-3 (blue) and
DENV-4 (black) using FACS-based neutralization assay. The y-axis corresponds to the observed percentage of virus infection in Vero cells. The dotted horizontal line
represents 50% infection. The x-axis corresponds to logarithm of reciprocal serum dilution. (B) Effect of EDIII-specific antibody depletion on the DENV-3 virus
neutralization potency of anti-DENV-3 E VLP antiserum. The same experiment as shown in panel A, except that the immune serum was pre-depleted with MBP
alone (blue) or MBP-EDIII-3 fusion protein (red) before being assessed for its neutralization potency against DENV-3 infection. Control serum (gray) was analyzed in
parallel without any pre-depletion with either MBP or MBP-EDIII-3 fusion protein.
sera to EDIII-3, we sought to understand the role of these
antibodies in the DENV-3 virus-neutralizing activity observed
above (Figure 3A). To this end, we performed an antibody
depletion experiment, as shown in Figure 3B. In this experiment,
we selectively depleted the EDIII-specific antibodies in the
immune serum by pre-incubating it with recombinant EDIII-3
protein (as an MBP fusion) and then determined the residual
DENV-3 neutralizing antibody titer. While a control depletion
(performed with MBP alone) produced a marginal decrease in
virus neutralizing antibody titer, depletion with EDIII-3 resulted
in a complete abrogation of virus neutralizing activity. Our
results very strongly support the conclusion that the DENV-3
neutralizing antibodies present in the DENV-3 E VLP-induced
immune serum are exclusively directed toward EDIII.
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That the P. pastoris-produced DENV-3 E VLPs contain
epitopes recognized by cross-reactive mAbs (Table 1) and
the antiserum raised using these VLPs contains cross-reactive
antibodies (Figure 2B) is evident from our observations above.
Would these cross-reactive antibodies play a role in facilitating
uptake of heterotypic DENVs through the Fc receptor pathway?
To address this, we examined the potential of the DENV-3 EVLP-
induced antibodies to cause enhancement. Fcγ receptor-bearing
K562 cells were infected with DENVs in the presence of varying
dilutions of the anti-DENV-3 E VLP antiserum, followed by
determination of the proportion of cells infected as a function of
immune serum dilution. For a comparison, serum from a DENV-
3 infected patient was also used in a parallel experiment. From the
results (Figure 4) it is evident that the patient serum manifested
significant heterotypic enhancement while the DENV-3 E VLP-
induced immune serum did not. A 20-fold dilution of the patient
serum resulted in ≥35% K-562 cells becoming infected with
DENV-1, -2, and -4 (heterotypic enhancement) with virtually no
DENV-3 infection. In contrast, a 20-fold dilution of anti-DENV-
3 E VLP antiserum manifested virtually insignificant heterotypic
enhancement effect on DENV-1, -2, and -4, and a low level of
homotypic enhancement of DENV-3 infection.
Discussion
We recently showed that a carboxy-terminally truncated version
of the E protein of DENV-2 expressed in P. pastoris could
assemble into discrete VLPs in the absence of any prM expression.
That these VLPs could elicit predominantly DENV-2 virus-
specific homotypic neutralizing antibodies underlined their
potential as alternate monovalent DENV-2 vaccine candidate
(Mani et al., 2013). Implicit in this finding is the possibility
that one could envisage a tetravalent DENV vaccine formulation
containing DENV E ectodomain-based VLPs of all four
serotypes. Realizing this possibility is contingent upon the
following three pre-requisites: (i) the E ectodomains of other
DENV serotypes expressed in P. pastoris should possess similar
VLP-forming potential; (ii) these VLPs should elicit high titer
serotype-specific neutralizing antibodies; (iii) further, these VLPs
should not manifest any potential for ADE. To this end, we
investigated the antigenic properties and immunogenicity of the
E ectodomain of a second DENV serotype, DENV-3, in this
paper.
We expressed DENV-3 E ectodomain (first 393 aa
residues), flanked by DENV-3 prM-derived signal peptide
at the N-terminus and a 6× His tag at the C-terminus, in
P. pastoris and purified it as before under denaturing conditions
using Ni2+-NTA affinity chromatography. The signal peptide
was found to be appropriately cleaved off and the protein was
found to be glycosylated as observed earlier for DENV-2 E
(Mani et al., 2013). Importantly, and as anticipated, the purified
DENV-3 E ectodomain protein was assembled into VLPs based
on EM and DLS analyses. This, taken together with our previous
work with DENV-2 E (Mani et al., 2013) and studies on HBsAg
(Lunsdorf et al., 2011), strongly suggest that that VLP assembly
of P. pastoris-produced viral antigens occurs post expression
during downstream processing.
Do the E VLPs maintain the antigenic integrity of E and
its domains especially as prM is absent? This was addressed
by epitope mapping using a battery of type-specific and cross-
reactive human and murine mAbs. Epitopes on EDI/II were
recognized by several serotype-specific mAbs (DENV-3 E mAbs
E3, E4, E12) as well as cross-reactive mAb E17. Reactivity of
mAbs 4G2, mAb h-1N5 and mAb h-1M7, indicated that the
fusion loop is intact. Importantly, epitopes of EDIII implicated
in the induction of type-specific neutralizing antibodies were
displayed appropriately on the surface of the DENV-3 E VLPs
based on the reactivity toward DENV-3 E mAb 8A1 (Wahala
et al., 2010), E77 (Brien et al., 2010), 12C1 (Wahala et al.,
2010), and DV1 E42 (Shrestha et al., 2010). All these antibodies
recognize epitopes in EDIII. The LR epitope, the major EDIII
target of strong neutralizing antibodies, is apparently intact based
on the reactivity of mAbs such as E77 and 8A1. The antigenic
FIGURE 4 | Antibody-dependent enhancement analysis. Serial dilutions (x-axis) of heat-inactivated anti-DENV-3 E VLP immune serum (A) or patient serum
(primary DENV-3 infection) were analyzed for their ability to promote uptake (y-axis) of DENV-1 (red), DENV-2 (green), DENV-3 (blue) or DENV-4 (black) into
Fcγ-bearing K562 cells, using a FACS-based enhancement assay. Note that y-axis in (B) is at a fivefold bigger scale compared to that in (A). Data from one of two
independent experiments are shown.
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structure of EDIII outside the LR is also preserved as the DENV-
3 E VLPs react with mAb 12C1, whose binding to EDIII is
unaffected by point mutations in LR epitope (Wahala et al., 2010).
The antigenic structure analysis is consistent with the P. pastoris-
produced DENV-3 E VLPs retaining the antigenic integrity of
the viral E antigen, particularly the EDIII, which is critical in the
induction of virus-neutralizing antibodies.
If the DENV-3 E VLPs indeed preserve antigenic integrity
of the E antigen and its sub-domains, especially EDIII, would
they elicit DENV-3 virus-specific antibodies? Would these be
capable of neutralizing DENV-3 infectivity? Our data show
that the P. pastoris-produced DENV-3 E VLPs are highly
immunogenic and elicit antibodies that specifically recognize
and bind to DENV-3 in infected cells. Further, in a FACS-based
neutralization assay, these antibodies manifested potent DENV-3
virus-neutralizing activity. The remarkable finding was that the
antiserum neither manifests significant levels of cross-reactivity
in ELISAs nor cross-neutralization of heterologous DENV
serotypes in the FACS assay. Significantly, selective depletion of
EDIII-specific antibodies from the immune serum resulted in loss
of DENV-3 neutralizing potency. Apparently, the neutralizing
activity elicited by DENV-3 E VLPs is solely associated with
the EDIII-specific fraction of the polyclonal response. This
conclusion is consistent with the notion that the DENV-3 E
VLPs presumably display EDIII efficiently on the VLP surface.
That DENV-2 E VLPs also elicit predominantly homotypic
neutralizing antibodies (Mani et al., 2013), is consistent with
this notion.
What is the infection-enhancing potential of the anti-DENV-
3 E VLP antibodies? As these VLPs do not contain prM, we
may rule out the elicitation of anti-prM antibodies implicated in
ADE (Dejnirattisai et al., 2010; Rodenhuis-Zybert et al., 2010)
of DENV infection. However, the identification of several cross-
reactive epitopes on the DENV-3 E VLPs (Table 1) suggests that
these can elicit cross-reactive antibodies. This is consistent with
the observed cross-reactivity of anti-DENV-3 E VLP antiserum
in ELISAs using DENV-2 E VLPs and heterologous recombinant
EDIIIs as coating antigens. Significantly, an ADE assay using
K562 cells, demonstrated that the anti-DENV-3 E VLP antiserum
did not possess discernible ADE activity on the infectivity of
heterologous DENV serotypes. This is consistent with the potent
and type-specific neutralizing antibody response elicited by
the DENV-3 E VLPs. We believe the observed low levels of
homotypic ADE to be an experimental phenomenon which may
be physiologically irrelevant. This notion draws support from
recent work using an in vivoADEmodel systemwhich shows that
type-specific neutralizing antibodies do not enhance infection at
any concentration (Watanabe et al., 2015).
This work extends and strengthens our previous observation
that the DENV E ectodomain expressed in P. pastoris can
assemble into immunogenic VLPs. These VLPs largely retain
the antigenic architecture of the viral epitopes critical for the
induction of potent virus-neutralizing antibodies. An analysis
of the epitope architecture on the VLP suggests that antigenic
integrity of the E protein is intact but subtly altered in way that
presents EDIII in a more accessible manner on the VLP surface.
The P. pastoris-produced DENV-3 VLPs presumably serve as
an efficient EDIII-display platform. This we believe underlies
the predominantly homotypic and EDIII-specific neutralizing
antibody response with inherently low potential for ADE.
Conclusion
The demonstration that DENV VLPs with promise of efficacy
and safety can be produced using P. pastoris, an expression
system that offers several key advantages from the perspective
of inexpensive vaccine production, in resource-poor countries
where dengue is endemic, strongly warrants further exploration
of this approach.
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